Nuclear imaging in the management of thyroid carcinoma

被引:28
作者
Cavalieri, RR
机构
[1] UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121
[2] UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94121
关键词
D O I
10.1089/thy.1996.6.485
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The avidity of differentiated thyroid carcinoma for iodine is the basis for the use of radioiodine (I-131) both for the detection and the treatment of recurrent thyroid cancer in patients following initial surgical treatment (thyroidectomy). Because recurrence of this type of cancer may be delayed for many years, long-term follow-up is needed. Nowadays such surveillance involves clinical assessment, monitoring of serum thyroglubulin, and, when indicated, whole-body imaging with I-131. Sensitivity of I-131 imaging depends on proper preparation of the patient and careful attention to imaging technique. Interpretation of images requires knowledge of physiologic sites of radioiodine concentration and causes of artifacts. Because of the potential suppressive effect of the radiation from a diagnostic administration of I-131 On the uptake of a subsequent therapeutic administration (so-called stunning of thyroid tissue) many centers limit the amount given for scanning to 2-3 mCi (74-111 MBq). Several tumor-seeking radioisotopic agents other than radioiodine have shown promise for improving the detection of metastases, and some of these agents offer a useful adjunct to I-131 in the management of selected patients, particularly in those with suspected metastatic disease and negative I-131 scans.
引用
收藏
页码:485 / 492
页数:8
相关论文
共 56 条
[1]  
ARNSTEIN NB, 1986, J NUCL MED, V27, P1764
[2]   SPURIOUS LUNG METASTASES ON RADIOIODINE THYROID AND WHOLE-BODY IMAGING [J].
BAKHEET, S ;
HAMMAMI, MM .
CLINICAL NUCLEAR MEDICINE, 1993, 18 (04) :307-312
[3]   FALSE-POSITIVE RADIOIODINE WHOLE-BODY SCAN IN THYROID-CANCER PATIENTS DUE TO UNRELATED PATHOLOGY [J].
BAKHEET, SM ;
HAMMAMI, MM .
CLINICAL NUCLEAR MEDICINE, 1994, 19 (04) :325-329
[4]  
BRENDEL AJ, 1988, J NUCL MED, V29, P1515
[5]  
BURMAN KD, 1990, J NUCL MED, V31, P1958
[6]   BONE SCANS IN BONE METASTASES FROM FUNCTIONING THYROID-CARCINOMA [J].
CASTILLO, LA ;
YEH, SDJ ;
LEEPER, RD ;
BENUA, RS .
CLINICAL NUCLEAR MEDICINE, 1980, 5 (05) :200-209
[7]  
CAVALIERI RR, 1996, THYROID, P352
[8]  
CHARKES ND, 1990, J NUCL MED, V31, P147
[9]  
COMTOIS R, 1993, J NUCL MED, V34, P1927
[10]  
DADPARVAR S, 1993, CANCER, V71, P3767, DOI 10.1002/1097-0142(19930601)71:11<3767::AID-CNCR2820711146>3.0.CO